Acquired Company

Astellas completed the acquisition of IVERIC bio on 7/11/2023 for US $40 per share in cash, acquiring all outstanding shares for approximately US $5.9 billion.

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Show more

1 Penn Plz Fl 35, New York, 10119-0002, US

www.ivericbio.com

Pharmaceutical Preparation Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$39.95

Open

$39.95

Volume

N/A

Day Range

$39.95 - $39.95

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.66%

Institutional Own.

Qtr Updated

03/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IZERVAY™ (avacincaptad pegol intravitreal solution) Details Age-related macular degeneration, Eye disease , Geographic atrophy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zimura (avacincaptad pegol) Details Macular degeneration, Autoimmune disease, Inflammatory disease	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.